WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it resubmitted its New Drug Application (NDA) for riboflavin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results